Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal

(2012) L Daelman et al.   Multiple Sclerosis Journal

Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings

(2012) F Rinaldi et al.   Multiple Sclerosis Journal

Lethal multiple sclerosis relapse after natalizumab withdrawal

(2012) V. Rigau et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

(2011) María José Magraner et al.   JOURNAL OF NEUROLOGY

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate

(2011) Joachim Havla et al.   JOURNAL OF NEUROLOGY

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated

(2010) Joep Killestein et al.   ANNALS OF NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

(2008) O. Stuve et al.   NEUROLOGY